---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002318"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:21:37.761416+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics raises $5.0M via warrant exercise; issues new warrants at $0.3006, subject to shareholder approval

## Summary
- Gross proceeds ~$5.0M from immediate cash exercise of 16.5M existing warrants at reduced exercise price of $0.3006/share.
- New unregistered Series A and Series B warrants each to purchase up to 16.5M shares at $0.3006; exercisable only after stockholder approval.
- Stockholder approval required to increase authorized shares and comply with Nasdaq Rule 5635(d); no voting rights until exercise.
- Maxim Group acted as agent; fees: 3.5% on Jan 2023 warrants and 7.0% on Nov 2023 warrants, plus up to $15,000 expense reimbursement.
- Company intends to use net proceeds for general corporate purposes; closing expected on or about January 9, 2024.

## SEC filing metadata
- accession: 0001104659-24-002318
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/tm242240d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002318
- JSON: https://secwatch.observer/filing/0001104659-24-002318.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002318.txt

## Key facts
- Material Agreements
  AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the Holders) valued at aggregate gross proceeds of approximately $5.0 million (effective 2025-01-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (the Holders)
  - Value: aggregate gross proceeds of approximately $5.0 million
  - Effective: 2025-01-05
  source text: On January 5, 2024, Avenue Therapeutics, Inc. (the “Company ”) entered into (i) an inducement offer letter agreement (the “ January 2023 Investor Inducement Letter ”) with a certain investor (the “ January 2023 Investor ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.